Elevate Your Health System with Comprehensive Risk Assessment
The Ambry CARE Program® (CARE) empowers health systems to identify high-risk patients who need additional screening and preventive care across multiple locations and service lines. Our digital platform automates breast cancer risk assessment and hereditary cancer testing qualification, helping you provide personalized, proactive care for every patient.
Are Your Patients Missing Critical High-Risk Care?
The Challenge:
Complex, evolving genetic testing guidelines
are difficult to interpret and apply manually.
Meeting NAPBC and other accreditation standards for high-risk screening and genetic evaluation is increasingly challenging.5
Deliver Personalized Care While Streamlining System-Wide Workflows
With CARE ("Comprehensive Assessment of Risk & Education"), your health system can:
Identify more high-risk patients through universal Tyrer-Cuzick scoring and automated hereditary cancer genetic testing qualification using the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®️).6,7
Streamline workflows with digital patient history collection, assessment, and genetic test ordering that integrates with your EHR.
Facilitate personalized care plans based on breast cancer risk scores and genetic test results.
Improve early detection with support to identify patients
who qualify for advanced screening like breast MRI.
Connect patients with education resources
and telehealth genetic counseling.
Trusted by Leading Health Systems
"At HCA Healthcare Sarah Cannon Cancer Network, our mission is to provide world-class cancer care in community settings. The Ambry CARE Program® has been instrumental in helping us deliver on this promise by making genetic and breast cancer risk assessments accessible to more patients. We've seen firsthand how this approach leads to earlier interventions and more personalized care plans for those at increased risk."
Dr. Dax Kurbegov - Vice President and Physician-In-Chief of Clinical Programs, HCA Healthcare Sarah Cannon Cancer Network
"The Ambry CARE Program has helped providers better identify minority patients that meet criteria for genetic testing and breast MRI and facilitate conversations about these services. The standardized questions have also helped reduce implicit bias since all patients receive the same questions, and all results are analyzed in the same way."
Chelsea Menke, MS, CGC – TriHealth Genetic Counselor & CARE Program Project Specialist
How CARE Works
Digital History Collection
Patients complete medical and family history questionnaires via text or email before appointments.
Automated Risk Assessment
CARE calculates Tyrer-Cuzick scores for all patients and evaluates hereditary cancer risk against NCCN Guidelines®.6,7 TC score can account for breast density.
Patient Education
Digital resources help patients understand their risk factors, genetic testing, and how results could affect their care and their families.
Streamlined Genetic Testing
If medically necessary, providers can order genetic testing through the CARE platform.
Results Delivery
Test results are delivered securely to providers and patients through the CARE platform.
Post-Test Genetic Counseling
Genetic counseling is available via telehealth to all patients.
Transparency at each step, improving the experience for providers and patients.
Validated by Clinical Research
CARE's hereditary risk assessment has been validated through rigorous research:8
- 99.5% accuracy (398/400 cases) in interpreting NCCN Guidelines®️6,7 to identify individuals appropriate for hereditary cancer testing
- Validated against real patient cases—validated using actual patient histories, not theoretical scenarios
- Proven across diverse clinical scenarios, including complex family histories
This validation confirms that CARE can consistently and accurately support the identification of at-risk patients across your entire health system.
Real Results from an Health System Using CARE
HCA Healthcare Sarah Cannon Cancer Network Achieved:9
- 75% completion rate for digital risk assessments
- ~1 in 3 patients identified as candidates for hereditary cancer testing or breast MRI based on TC score
- 8% of patients had a change in recommended clinical management
- Successfully deployed across multiple community hospitals, demonstrating CARE enables system-wide implementation
"I'm so grateful for HCA and the Ambry CARE Program. I'm grateful for the extra years I may be able to spend with my children and, hopefully someday, grandchildren because of the proactive healthcare choices I've been able to make."
Christina Peratos — HCA Florida Ocala Hospital Patient, BRCA2+
Transform Your Practice with CARE
Implementing CARE at your imaging center means:
For Patients
Support them with personalized care plans that promote earlier detection and may reduce their cancer risk.
For Providers
Streamline your workflows, automate documentation, and leverage tools that will support you in providing guideline-concordant care.
For Your Practice
Consistently connect qualified patients with high-risk services, improve patient satisfaction, and differentiate from competitors.
For Your System
Standardize care across all locations, meet quality metrics and accreditation requirements, ensure regulatory compliance, and build a financially sustainable high-risk program.
Ready to Elevate Your High-Risk Screening or Population Health Program?
Additional Resources
- CARE Health System Flyer
- CARE Clinician Perspective: CARE Provider Quotes Video
- CARE Patient Perspective: Blog & Interview with BRCA2+ CARE patient
- CARE Patient Experience Video
References
- Miles R, et aI. (2018) PMID: 29341851
- Hill, D. A., et al. (2017). https://doi.org/10.1007/s11606-017-4224-6
- Caswell-Jin, J. L., et al. (2019). https://doi.org/10.1093/jnci/djy147
- Wildin, R. S., et al. (2021). https://doi.org/10.1007/s12687-021-00531-6
- National Accreditation Program for Breast Centers. (2024). Optimal Resources for Breast Care (2024 Standards). American College of Surgeons.
- Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate. V3.2025. ©National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed April 2, 2025. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
- Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Genetic/Familial High-Risk Assessment: Colorectal, Endometrial, and Gastric. V4.2024. ©National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed April 2, 2025. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
- Fecteau, H., Pfleger, H., Nathan, D., Siddiqui, S., Horton, C., Pilarski, R., Ryan, E., Thrush, D., Ranola, J., Clifford, J., Lyon, L., & Kieran, S. (in press). Validation of a digital tool that uses national testing guidelines to identify individuals at risk for hereditary cancer. JNCCN: Journal of the National Comprehensive Cancer Network.
- Fecteau, H., et al. (2023). A scalable approach to democratizing cancer risk stratification: One healthcare system's approach using a patient-facing digital platform. Journal of Clinical Oncology, 41(16_suppl), 10622-10622. https://doi.org/10.1200/JCO.2023.41.16_suppl.10622
Questions? Contact Us.
info@ambrygen.com (949) 900-5500